X4 Pharmaceuticals (XFOR) Stock Statistics & Valuation Metrics

X4 Pharmaceuticals has a market cap or net worth of $319.14M. The enterprise value is $102.93M.

X4 Pharmaceuticals has 87,436,690 shares outstanding. The number of shares has decreased by -2.65% in one year.

X4 Pharmaceuticals’s return on equity (ROE) is -1.69 and return on invested capital (ROIC) is -31.97%.

The current PE Ratio of X4 Pharmaceuticals is ―. X4 Pharmaceuticals’s PEG ratio is 0.06.

In the last 12 months, X4 Pharmaceuticals had revenue of 2.56M and earned -37.45M in profits. Earnings per share was -5.59.

In the last 12 months, operating cash flow was -103.09M and capital expenditures -3.04M, giving a free cash flow of -106.13M billion.

X4 Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

X4 Pharmaceuticals upcoming earnings date is Mar 12, 2026, Before Open (Confirmed).

X4 Pharmaceuticals as a current ratio of 3.41, with Debt / Equity ratio of 54.97%

In the past 12 months, X4 Pharmaceuticals has paid 310.00K in taxes.

X4 Pharmaceuticals EV to EBITDA ratio is -6.16, with an EV/FCF ratio of -1.29.

X4 Pharmaceuticals has $122.42M in cash and marketable securities with $77.36M in debt, giving a net cash position of $45.06M billion.

Gross margin is 83.00%, with operating margin of -1423.58%, and net profit margin of -1464.61%.

The average price target for X4 Pharmaceuticals is $6.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy